Heparanase: From basic research to therapeutic applications in cancer and inflammation

Drug Resistance Updates

Volumn 29, Issue , 2016, Pages 54-75

  Vlodavsky, Israel ^a   Singh, Preeti ^a   Boyango, Ilanit ^a   Gutter Kapon, Lilach ^a   Elkin, Michael ^b   Sanderson, Ralph D ^c   Ilan, Neta ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c University of Alabama at Birmingham   (United States)

Author keywords

Autophagy; Chemoresistance; Clinical trials; Exosomes; Heparanase; Heparanase inhibiting compounds; Inflammation; Tumorigenesis

Indexed keywords

ALPHA ACTININ; ANTINEOPLASTIC AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPARAN SULFATE; HEPARANASE; HEPARANASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEOHEPARAN SULFATE; SYNDECAN 1; SYNTENIN; TOBACCO SMOKE; BETA GLUCURONIDASE; GLYCOSIDASE INHIBITOR; TUMOR PROTEIN;

ANGIOGENESIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DOWN REGULATION; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME STRUCTURE; EXOSOME; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG; LYMPHOMA; MACROPHAGE; METASTASIS; MYELOMA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SEPSIS; TUMOR MICROENVIRONMENT; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84991768946     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2016.10.001     Document Type: Article

References (265)

1. Aalkjaer, C., Boedtkjer, D.B., Getting neointimal: the emergence of heparanase into the vascular matrix. Circ. Res. 104 (2009), 277–279.
2. Abboud-Jarrous, G., Rangini-Guetta, Z., Aingorn, H., Atzmon, R., Elgavish, S., Peretz, T., Vlodavsky, I., Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J. Biol. Chem. 280 (2005), 13568–13575.
3. Abboud-Jarrous, G., Atzmon, R., Peretz, T., Palermo, C., Gadea, B.B., Joyce, J.A., Vlodavsky, I., Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem. 283 (2008), 18167–18176.
4. Akbarshahi, H., Axelsson, J.B., Said, K., Malmstrom, A., Fischer, H., Andersson, R., TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J. Transl. Med., 9, 2011, 219.
5. Allen, B.L., Filla, M.S., Rapraeger, A.C., Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition. J. Cell Biol. 155 (2001), 845–858.
6. Ansell, S.M., Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin. Proc. 90 (2015), 1152–1163.
7. Arvatz, G., Barash, U., Nativ, O., Ilan, N., Vlodavsky, I., Post-transcriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J. 24 (2011), 4969–4976.
8. Arvatz, G., Shafat, I., Levy-Adam, F., Ilan, N., Vlodavsky, I., The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev. 30 (2011), 253–268.
9. Au Yeung, C.L., Co, N.N., Tsuruga, T., Yeung, T.L., Kwan, S.Y., Leung, C.S., Li, Y., Lu, E.S., Kwan, K., Wong, K.K., Schmandt, R., Lu, K.H., Mok, S.C., Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat. Commun., 7, 2016, 11150.
10. Axelsson, J., Xu, D., Kang, B.N., Nussbacher, J.K., Handel, T.M., Ley, K., Sriramarao, P., Esko, J.D., Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120 (2012), 1742–1751.
11. Baietti, M.F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson, Y., Depoortere, F., Coomans, C., Vermeiren, E., Zimmermann, P., David, G., Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14 (2012), 677–685.
12. Baker, A.B., Groothuis, A., Jonas, M., Ettenson, D.S., Shazly, T., Zcharia, E., Vlodavsky, I., Seifert, P., Edelman, E.R., Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ. Res. 104 (2009), 380–387.
13. Baker, A.B., Gibson, W.J., Kolachalama, V.B., Golomb, M., Indolfi, L., Spruell, C., Zcharia, E., Vlodavsky, I., Edelman, E.R., Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J. Am. Coll. Cardiol. 59 (2012), 1551–1560.
14. Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R.D., Ilan, N., Vlodavsky, I., Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 277 (2010), 3890–3903.
15. Barash, U., Zohar, Y., Wildbaum, G., Beider, K., Nagler, A., Karin, N., Ilan, N., Vlodavsky, I., Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 28 (2014), 2178–2187.
16. Baumgart, S., Ellenrieder, V., Fernandez-Zapico, M.E., Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut 62 (2013), 310–316.
17. Bayer-Garner, I.B., Sanderson, R.D., Dhodapkar, M.V., Owens, R.B., Wilson, C.S., Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol. 14 (2001), 1052–1058.
18. Beauvais, D.M., Rapraeger, A.C., Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol., 2, 2004, 3.
19. Beauvais, D.M., Jung, O., Yang, Y., Sanderson, R.D., Rapraeger, A.C., Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Res. 76 (2016), 4981–4993 (PMID: 27364558).
20. Belmiro, C.L., Souza, H.S., Elia, C.C., Castelo-Branco, M.T., Silva, F.R., Machado, R.L., Pavao, M.S., Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int. J. Colorectal Dis. 20 (2005), 295–304.
21. Ben-Zaken, O., Shafat, I., Gingis-Velitski, S., Bangio, H., Kelson, I.K., Alergand, T., Amor, Y., Maya, R.B., Vlodavsky, I., Ilan, N., Low and high affinity receptors mediate cellular uptake of heparanase. Int. J. Biochem. Cell Biol. 40 (2008), 530–542.
22. Benhamron, S., Nechushtan, H., Verbovetski, I., Krispin, A., Abboud-Jarrous, G., Zcharia, E., Edovitsky, E., Nahari, E., Peretz, T., Vlodavsky, I., Mevorach, D., Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J. Immunol. 176 (2006), 6417–6424.
23. Benhamron, S., Reiner, I., Zcharia, E., Atallah, M., Grau, A., Vlodavsky, I., Mevorach, D., Dissociation between mature phenotype and impaired transmigration in dendritic cells from heparanase-deficient mice. PLoS One, 7, 2012, e35602.
24. Bernfield, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., Zako, M., Functions of cell surface heparan sulfate proteoglycans. Ann. Rev. Biochem. 68 (1999), 729–777.
25. Blich, M., Golan, A., Arvatz, G., Sebbag, A., Shafat, I., Sabo, E., Cohen-Kaplan, V., Petcherski, S., Avniel-Polak, S., Eitan, A., Hammerman, H., Aronson, D., Axelman, E., Ilan, N., Nussbaum, G., Vlodavsky, I., Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler. Thromb. Vasc. Biol. (ATVB) 33 (2012), e56–e65.
26. Blonska, M., Agarwal, N.K., Vega, F., Shaping of the tumor microenvironment: stromal cells and vessels. Semin. Cancer Biol. 34 (2015), 3–13 (PMID: 25794825).
27. Bode, L., Salvestrini, C., Park, P.W., Li, J.P., Esko, J.D., Yamaguchi, Y., Murch, S., Freeze, H.H., Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J. Clin. Investig. 118 (2008), 229–238.
28. Bode, J.G., Ehlting, C., Haussinger, D., The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 24 (2012), 1185–1194.
29. Boyango, I., Barash, U., Naroditsky, I., Li, J.P., Hammond, E., Ilan, N., Vlodavsky, I., Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res. 74 (2014), 4504–4514.
30. Brennan, T.V., Lin, L., Brandstadter, J.D., Rendell, V.R., Dredge, K., Huang, X., Yang, Y., Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J. Clin. Investig. 126 (2016), 207–219.
31. Brun, R., Naroditsky, I., Waterman, M., Ben-Izhak, O., Groisman, G., Ilan, N., Vlodavsky, I., Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod. Pathol. 22 (2009), 1548–1554.
32. Brunn, G.J., Bungum, M.K., Johnson, G.B., Platt, J.L., Conditional signaling by Toll-like receptor 4. FASEB J. 19 (2005), 872–874.
33. Cantarel, B.L., Coutinho, P.M., Rancurel, C., Bernard, T., Lombard, V., Henrissat, B., The Carbohydrate-Active EnZymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res. 37 (2009), D233–D238.
34. Cao, H.J., Fang, Y., Zhang, X., Chen, W.J., Zhou, W.P., Wang, H., Wang, L.B., Wu, J.M., Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue. World J. Gastroenterol. 11 (2005), 903–907.
35. Cassinelli, G., Lanzi, C., Tortoreto, M., Cominetti, D., Petrangolini, G., Favini, E., Zaffaroni, N., Pisano, C., Penco, S., Vlodavsky, I., Zunino, F., Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem. Pharmacol. 85 (2013), 1424–1432.
36. Cassinelli, G., Favini, E., Dal Bo, L., Tortoreto, M., De Maglie, M., Dagrada, G., Pilotti, S., Zunino, F., Zaffaroni, N., Lanzi, C., Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget, 2016 (PMID: 27374103).
37. Chiba, T., Marusawa, H., Ushijima, T., Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143 (2012), 550–563.
38. Clayburgh, D.R., Shen, L., Turner, J.R., A porous defense: the leaky epithelial barrier in intestinal disease. Lab. Investig. 84 (2004), 282–291.
39. Cohen-Kaplan, V., Doweck, I., Naroditsky, I., Vlodavsky, I., Ilan, N., Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res. 68 (2008), 10077–10085.
40. Cohen-Kaplan, V., Naroditsky, I., Zetser, A., Ilan, N., Vlodavsky, I., Doweck, I., Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 123 (2008), 2566–2573.
41. Cohen-Kaplan, V., Jrbashyan, J., Yanir, Y., Naroditsky, I., Ben-Izhak, O., Ilan, N., Doweck, I., Vlodavsky, I., Heparanase induces Signal Transducer and Activator of Transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J. Biol. Chem. 287 (2012), 6668–6678.
42. Constantinescu, A.A., Vink, H., Spaan, J.A., Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler. Thromb. Vasc. Biol. (ATVB) 23 (2003), 1541–1547.
43. David, G., Zimmermann, P., Heparanase tailors syndecan for exosome production. Mol. Cell. Oncol., 3, 2016, e1047556.
44. Davies, G., Henrissat, B., Structures and mechanisms of glycosyl hydrolases. Structure 3 (1995), 853–859.
45. Day, R., Forbes, A., Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354 (1999), 62–65.
46. de Mestre, A.M., Staykova, M.A., Hornby, J.R., Willenborg, D.O., Hulett, M.D., Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J. Leukoc. Biol. 82 (2007), 1289–1300.
47. Di Marzo, L., Desantis, V., Solimando, A.G., Ruggieri, S., Annese, T., Nico, B., Fumarulo, R., Vacca, A., Frassanito, M.A., Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget(July), 2016.
48. Doviner, V., Maly, B., Kaplan, V., Gingis-Velitski, S., Ilan, N., Vlodavsky, I., Sherman, Y., Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod. Pathol. 19 (2006), 878–888.
49. Doweck, I., Kaplan-Cohen, V., Naroditsky, I., Sabo, E., Ilan, N., Vlodavsky, I., Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8 (2006), 1055–1061.
50. Dredge, K., Hammond, E., Davis, K., Li, C.P., Liu, L., Johnstone, K., Handley, P., Wimmer, N., Gonda, T.J., Gautam, A., Ferro, V., Bytheway, I., The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Investig. New Drugs 28 (2010), 276–283.
51. Dredge, K., Hammond, E., Handley, P., Gonda, T.J., Smith, M.T., Vincent, C., Brandt, R., Ferro, V., Bytheway, I., PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 104 (2011), 635–642.
52. Dunlop, E.A., Tee, A.R., mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin. Cell Dev. Biol. 36 (2014), 121–129.
53. Edovitsky, E., Elkin, M., Zcharia, E., Peretz, T., Vlodavsky, I., Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl. Cancer Inst. 96 (2004), 1219–1230.
54. Edovitsky, E., Lerner, I., Zcharia, E., Peretz, T., Vlodavsky, I., Elkin, M., Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107 (2006), 3609–3616.
55. Egeberg, M., Kjeken, R., Kolset, S.O., Berg, T., Prydz, K., Internalization and stepwise degradation of heparan sulfate proteoglycans in rat hepatocytes. Biochim. Biophys. Acta 1541 (2001), 135–149.
56. El-Assal, O.N., Yamanoi, A., Ono, T., Kohno, H., Nagasue, N., The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 7 (2001), 1299–1305.
57. Elkin, M., Ilan, N., Ishai-Michaeli, R., Friedmann, Y., Papo, O., Pecker, I., Vlodavsky, I., Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15 (2001), 1661–1663.
58. Escobar Galvis, M.L., Jia, J., Zhang, X., Jastrebova, N., Spillmann, D., Gottfridsson, E., van Kuppevelt, T.H., Zcharia, E., Vlodavsky, I., Lindahl, U., Li, J.P., Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat. Chem. Biol. 3 (2007), 773–778.
59. Fang, H., Declerck, Y.A., Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 73 (2013), 4965–4977.
60. Feig, C., Gopinathan, A., Neesse, A., Chan, D.S., Cook, N., Tuveson, D.A., The pancreas cancer microenvironment. Clin. Cancer Res. 18 (2012), 4266–4276.
61. Ferro, V., Dredge, K., Liu, L., Hammond, E., Bytheway, I., Li, C., Johnstone, K., Karoli, T., Davis, K., Copeman, E., Gautam, A., PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 33 (2007), 557–568.
62. Floer, M., Gotte, M., Wild, M.K., Heidemann, J., Gassar, E.S., Domschke, W., Kiesel, L., Luegering, A., Kucharzik, T., Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am. J. Pathol. 176 (2010), 146–157.
63. Friand, V., David, G., Zimmermann, P., Syntenin and syndecan in the biogenesis of exosomes. Biol. Cell 107 (2015), 331–341.
64. Fux, L., Feibish, N., Cohen-Kaplan, V., Gingis-Velitski, S., Feld, S., Geffen, C., Vlodavsky, I., Ilan, N., Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 69 (2009), 1758–1767.
65. Fux, L., Ilan, N., Sanderson, R.D., Vlodavsky, I., Heparanase: busy at the cell surface. Trends Biochem. Sci. 34 (2009), 511–519.
66. Garsen, M., Benner, M., Dijkman, H.B., van Kuppevelt, T.H., Li, J.P., Rabelink, T.J., Vlodavsky, I., Berden, J.H., Rops, A.L., Elkin, M., van der Vlag, J., Heparanase is essential for the development of acute experimental glomerulonephritis. Am. J. Pathol. 186 (2016), 805–815.
67. Garsen, M., Lenoir, O., Rops, A.L., Dijkman, H.B., Willemsen, B., van Kuppevelt, T.H., Rabelink, T.J., Berden, J.H., Tharaux, P.L., van der Vlag, J., Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J. Am. Soc. Nephrol. (JASN), 2016 (PMID: 27026367).
68. Gil, N., Goldberg, R., Neuman, T., Garsen, M., Zcharia, E., Rubinstein, A.M., van Kuppevelt, T., Meirovitz, A., Pisano, C., Li, J.P., van der Vlag, J., Vlodavsky, I., Elkin, M., Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61 (2012), 208–216.
69. Gingis-Velitski, S., Zetser, A., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J. Biol. Chem. 279 (2004), 23536–23541.
70. Gingis-Velitski, S., Zetser, A., Kaplan, V., Ben-Zaken, O., Cohen, E., Levy-Adam, F., Bashenko, Y., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279 (2004), 44084–44092.
71. Goldberg, R., Meirovitz, A., Hirshoren, N., Bulvik, R., Binder, A., Rubinstein, A.M., Elkin, M., Versatile role of heparanase in inflammation. Matrix Biol. 32 (2013), 234–240.
72. Goldberg, R., Rubinstein, A.M., Gil, N., Hermano, E., Li, J.P., van der Vlag, J., Atzmon, R., Meirovitz, A., Elkin, M., Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 63 (2014), 4302–4313.
73. Goldshmidt, O., Nadav, L., Aingorn, H., Irit, C., Feinstein, N., Ilan, N., Zamir, E., Geiger, B., Vlodavsky, I., Katz, B.Z., Human heparanase is localized within lysosomes in a stable form. Exp. Cell Res. 281 (2002), 50–62.
74. Goodall, K.J., Poon, I.K., Phipps, S., Hulett, M.D., Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One, 9, 2014, e109596.
75. Gotte, M., Syndecans in inflammation. FASEB J. 17 (2003), 575–591.
76. Grivennikov, S.I., Karin, M., Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20 (2010), 65–71.
77. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
78. Gross-Cohen, M., Feld, S., Doweck, I., Neufeld, G., Hasson, P., Arvatz, G., Barash, U., Naroditsky, I., Ilan, N., Vlodavsky, I., Heparanase 2 attenuates head and neck tumor vascularity and growth. Cancer Res. 76 (2016), 2791–2801.
79. Gross-Cohen, M., Feld, S., Naroditsky, I., Nativ, O., Ilan, N., Vlodavsky, I., Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. Oncotarget 7 (2016), 22556–22565.
80. Guo, C.H., Koo, C.Y., Bay, B.H., Tan, P.H., Yip, G.W., Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int. J. Oncol. 31 (2007), 1415–1423.
81. Gupta, R.B., Harpaz, N., Itzkowitz, S., Hossain, S., Matula, S., Kornbluth, A., Bodian, C., Ullman, T., Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133 (2007), 1099–1105 (quiz 1340–1091).
82. Hacker, U., Nybakken, K., Perrimon, N., Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 6 (2005), 530–541.
83. Hadigal, S.R., Agelidis, A.M., Karasneh, G.A., Antoine, T.E., Yakoub, A.M., Ramani, V.C., Djalilian, A.R., Sanderson, R.D., Shukla, D., Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. Nat. Commun., 6, 2015, 6985.
84. Hammond, E., Li, C.P., Ferro, V., Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening. Anal. Biochem. 396 (2011), 112–116.
85. Hammond, E., Brandt, R., Dredge, K., PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One, 7, 2012, e52175.
86. Hammond, E., Khurana, A., Shridhar, V., Dredge, K., The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front. Oncol., 4, 2014, 195.
87. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
88. He, Y.Q., Sutcliffe, E.L., Bunting, K.L., Li, J., Goodall, K.J., Poon, I.K., Hulett, M.D., Freeman, C., Zafar, A., McInnes, R.L., Taya, T., Parish, C.R., Rao, S., The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3 (2012), 130–145.
89. Hermano, E., Lerner, I., Elkin, M., Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell. Mol. Life Sci. 69 (2012), 2501–2513.
90. Hermano, E., Meirovitz, A., Meir, K., Nussbaum, G., Appelbaum, L., Peretz, T., Elkin, M., Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J. Natl. Cancer Inst., 106, 2014.
91. Hershkoviz, R., Mor, F., Miao, H.Q., Vlodavsky, I., Lider, O., Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity. J. Autoimmun. 8 (1995), 741–750.
92. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D., Anderson, K.C., Bortezomib induces canonical nuclear factor-kappa B activation in multiple myeloma cells. Blood 114 (2009), 1046–1052.
93. Hiraoka, N., Ino, Y., Sekine, S., Tsuda, H., Shimada, K., Kosuge, T., Zavada, J., Yoshida, M., Yamada, K., Koyama, T., Kanai, Y., Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br. J. Cancer 103 (2010), 1057–1065.
94. Hoffmann, A.C., Mori, R., Vallbohmer, D., Brabender, J., Drebber, U., Baldus, S.E., Klein, E., Azuma, M., Metzger, R., Hoffmann, C., Hoelscher, A.H., Danenberg, K.D., Prenzel, K.L., Danenberg, P.V., High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J. Gastrointest. Surg. 12 (2008), 1674–1681.
95. Hulett, M.D., Hornby, J.R., Ohms, S.J., Zuegg, J., Freeman, C., Gready, J.E., Parish, C.R., Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39 (2000), 15659–15667.
96. Ijichi, H., Chytil, A., Gorska, A.E., Aakre, M.E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., Ikenoue, T., Tateishi, K., Wright, C.V., Koike, K., Omata, M., Moses, H.L., Inhibiting Cxcr2 disrupts tumor–stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Investig. 121 (2011), 4106–4117.
97. Ilan, N., Elkin, M., Vlodavsky, I., Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 38 (2006), 2018–2039.
98. Ilan, N., Shteingauz, A., Vlodavsky, I., Function from within: autophagy induction by HPSE/heparanase—new possibilities for intervention. Autophagy 11 (2015), 2387–2389.
99. Iozzo, R.V., Sanderson, R.D., Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 15 (2011), 1013–1031.
100. Johnson, G.B., Brunn, G.J., Kodaira, Y., Platt, J.L., Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168 (2002), 5233–5239.
101. Jones, S.A., Scheller, J., Rose-John, S., Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Investig. 121 (2011), 3375–3383.
102. Jung, D.B., Yun, M., Kim, E.O., Kim, J., Kim, B., Jung, J.H., Wang, E., Mukhopadhyay, D., Hammond, E., Dredge, K., Shridhar, V., Kim, S.H., The heparan sulfate mimetic PG545 interferes with Wnt/beta-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget 6 (2015), 4992–5004.
103. Jung, O., Trapp-Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R.D., Rapraeger, A.C., Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis, 5, 2016, e202.
104. Kato, M., Wang, H., Kainulainen, V., Fitzgerald, M.L., Ledbetter, S., Ornitz, D.M., Bernfield, M., Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4 (1998), 691–697.
105. Kelly, T., Miao, H.-Q., Yang, Y., Navarro, E., Kussie, P., Huang, Y., MacLeod, V., Casciano, J., Joseph, L., Zhan, F., Zangari, M., Barlogie, B., Shaughnessy, J., Sanderson, R.D., High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 63 (2003), 8749–8756.
106. Koliopanos, A., Friess, H., Kleeff, J., Shi, X., Liao, Q., Pecker, I., Vlodavsky, I., Zimmermann, A., Buchler, M.W., Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 61 (2001), 4655–4659.
107. Kopp, A., Buechler, C., Neumeier, M., Weigert, J., Aslanidis, C., Scholmerich, J., Schaffler, A., Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring) 17 (2009), 648–656.
108. Korolchuk, V.I., Saiki, S., Lichtenberg, M., Siddiqi, F.H., Roberts, E.A., Imarisio, S., Jahreiss, L., Sarkar, S., Futter, M., Menzies, F.M., O'Kane, C.J., Deretic, V., Rubinsztein, D.C., Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 13 (2011), 453–460.
109. Kudchadkar, R., Gonzalez, R., Lewis, K.D., PI-88: a novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 17 (2008), 1769–1776.
110. Lapidot, M., Barash, U., Zohar, Y., Geffen, Y., Naroditsky, I., Ilan, N., Best, L.A., Vlodavsky, I., Involvement of heparanase in empyema: implication for novel therapeutic approaches. J. Clin. Cell. Immunol., 6(1), 2015 (PMID 26005591).
111. Larrue, C., Saland, E., Boutzen, H., Vergez, F., David, M., Joffre, C., Hospital, M.A., Tamburini, J., Delabesse, E., Manenti, S., Sarry, J.E., Recher, C., Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood 127 (2016), 882–892.
112. Laubach, J.P., Voorhees, P.M., Hassoun, H., Jakubowiak, A., Lonial, S., Richardson, P.G., Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev. Hematol. 7 (2014), 97–111.
113. Ledin, J., Staatz, W., Li, J.P., Gotte, M., Selleck, S., Kjellen, L., Spillmann, D., Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279 (2004), 42732–42741.
114. Lerner, I., Baraz, L., Pikarsky, E., Meirovitz, A., Edovitsky, E., Peretz, T., Vlodavsky, I., Elkin, M., Function of heparanase in prostate tumorigenesis: potential for therapy. Clin. Cancer Res. 14 (2008), 668–676.
115. Lerner, I., Hermano, E., Zcharia, E., Rodkin, D., Bulvik, R., Doviner, V., Rubinstein, A.M., Ishai-Michaeli, R., Atzmon, R., Sherman, Y., Meirovitz, A., Peretz, T., Vlodavsky, I., Elkin, M., Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Investig. 121 (2011), 1709–1721.
116. Lerner, I., Zcharia, E., Neuman, T., Hermano, E., Rubinstein, A.M., Vlodavsky, I., Elkin, M., Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice. Cell. Mol. Life Sci. (CMLS) 71 (2014), 2347–2357.
117. Lesina, M., Kurkowski, M.U., Ludes, K., Rose-John, S., Treiber, M., Kloppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., Schmid, R.M., Algul, H., Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19 (2011), 456–469.
118. Levy, J.M., Thorburn, A., Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol. Ther. 131 (2011), 130–141.
119. Levy-Adam, F., Miao, H.Q., Heinrikson, R.L., Vlodavsky, I., Ilan, N., Heterodimer formation is essential for heparanase enzymatic activity. Biochem. Biophys. Res. Commun. 308 (2003), 885–891.
120. Levy-Adam, F., Abboud-Jarrous, G., Guerrini, M., Beccati, D., Vlodavsky, I., Ilan, N., Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J. Biol. Chem. 280 (2005), 20457–20466.
121. Levy-Adam, F., Feld, S., Suss-Toby, E., Vlodavsky, I., Ilan, N., Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One, 3, 2008, e2319.
122. Levy-Adam, F., Feld, S., Cohen-Kaplan, V., Shteingauz, A., Gross, M., Arvatz, G., Naroditsky, I., Ilan, N., Doweck, I., Vlodavsky, I., Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J. Biol. Chem. 285 (2010), 28010–28019.
123. Li, J.P., Vlodavsky, I., Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 102 (2009), 823–828.
124. Li, J.P., Galvis, M.L., Gong, F., Zhang, X., Zcharia, E., Metzger, S., Vlodavsky, I., Kisilevsky, R., Lindahl, U., In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 6473–6477.
125. Li, R.W., Freeman, C., Yu, D., Hindmarsh, E.J., Tymms, K.E., Parish, C.R., Smith, P.N., Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheumatol. 58 (2008), 1590–1600.
126. Li, L., Wang, B., Gao, T., Zhang, X., Hao, J.X., Vlodavsky, I., Wiesenfeld-Hallin, Z., Xu, X.J., Li, J.P., Heparanase overexpression reduces carrageenan-induced mechanical and cold hypersensitivity in mice. Neurosci. Lett. 511 (2012), 4–7.
127. Li, Y., Liu, H., Huang, Y.Y., Pu, L.J., Zhang, X.D., Jiang, C.C., Jiang, Z.W., Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase. Int. J. Mol. Med. 31 (2013), 1234–1242.
128. Lider, O., Baharav, E., Mekori, Y.A., Miller, T., Naparstek, Y., Vlodavsky, I., Cohen, I.R., Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Investig. 83 (1989), 752–756.
129. Lider, O., Mekori, Y.A., Miller, T., Bar-Tana, R., Vlodavsky, I., Baharav, E., Cohen, I.R., Naparstek, Y., Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 20 (1990), 493–499.
130. Lindahl, U., Li, J.P., Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol. 276 (2009), 105–159.
131. Liu, C.J., Chang, J., Lee, P.H., Lin, D.Y., Wu, C.C., Jeng, L.B., Lin, Y.J., Mok, K.T., Lee, W.C., Yeh, H.Z., Ho, M.C., Yang, S.S., Yang, M.D., Yu, M.C., Hu, R.H., Peng, C.Y., Lai, K.L., Chang, S.S., Chen, P.J., Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J. Gastroenterol. 20 (2014), 11384–11393.
132. Lowenfels, A.B., Maisonneuve, P., Cavallini, G., Ammann, R.W., Lankisch, P.G., Andersen, J.R., Dimagno, E.P., Andren-Sandberg, A., Domellof, L., Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328 (1993), 1433–1437.
133. Mahtouk, K., Hose, D., Raynaud, P., Hundemer, M., Jourdan, M., Jourdan, E., Pantesco, V., Baudard, M., De Vos, J., Larroque, M., Moehler, T., Rossi, J.F., Reme, T., Goldschmidt, H., Klein, B., Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109 (2007), 4914–4923.
134. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
135. Massena, S., Christoffersson, G., Hjertstrom, E., Zcharia, E., Vlodavsky, I., Ausmees, N., Rolny, C., Li, J.P., Phillipson, M., A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116 (2011), 1924–1931.
136. Matzner, Y., Bar-Ner, M., Yahalom, J., Ishai-Michaeli, R., Fuks, Z., Vlodavsky, I., Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J. Clin. Investig. 76 (1985), 1306–1313.
137. McKenzie, E.A., Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 151 (2007), 1–14.
138. McKenzie, E., Tyson, K., Stamps, A., Smith, P., Turner, P., Barry, R., Hircock, M., Patel, S., Barry, E., Stubberfield, C., Terrett, J., Page, M., Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem. Biophys. Res. Commun. 276 (2000), 1170–1177.
139. McKown, R.L., Wang, N., Raab, R.W., Karnati, R., Zhang, Y., Williams, P.B., Laurie, G.W., Lacritin and other new proteins of the lacrimal functional unit. Exp. Eye Res. 88 (2009), 848–858.
140. Meads, M.B., Hazlehurst, L.A., Dalton, W.S., The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14 (2008), 2519–2526.
141. Mehta-Shah, N., Younes, A., Novel targeted therapies in diffuse large B-cell lymphoma. Semin. Hematol. 52 (2015), 126–137.
142. Meirovitz, A., Hermano, E., Lerner, I., Zcharia, E., Pisano, C., Peretz, T., Elkin, M., Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res. 71 (2011), 2772–2780.
143. Mitsiades, C.S., Rouleau, C., Echart, C., Menon, K., Teicher, B., Distaso, M., Palumbo, A., Boccadoro, M., Anderson, K.C., Iacobelli, M., Richardson, P.G., Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin. Cancer Res. 15 (2009), 1210–1221.
144. Mizgerd, J.P., Kubo, H., Kutkoski, G.J., Bhagwan, S.D., Scharffetter-Kochanek, K., Beaudet, A.L., Doerschuk, C.M., Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18-deficient mice. J. Exp. Med. 186 (1997), 1357–1364.
145. Morris, A., Wang, B., Waern, I., Venkatasamy, R., Page, C., Schmidt, E.P., Wernersson, S., Li, J.P., Spina, D., The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One, 10, 2015, e0127032.
146. Murch, S.H., MacDonald, T.T., Walker-Smith, J.A., Levin, M., Lionetti, P., Klein, N.J., Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341 (1993), 711–714.
147. Nadav, L., Eldor, A., Yacoby-Zeevi, O., Zamir, E., Pecker, I., Ilan, N., Geiger, B., Vlodavsky, I., Katz, B.Z., Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J. Cell Sci. 115 (2002), 2179–2187.
148. Nadir, Y., Brenner, B., Zetser, A., Ilan, N., Shafat, I., Zcharia, E., Goldshmidt, O., Vlodavsky, I., Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J. Thromb. Haemost. 4 (2006), 2443–2451.
149. Nadir, Y., Brenner, B., Fux, L., Shafat, I., Attias, J., Vlodavsky, I., Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 95 (2010), 1927–1934.
150. Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., Pisano, C., Giannini, G., Ishai-Michaeli, R., Vlodavsky, I., Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 280 (2005), 12103–12113.
151. Naomoto, Y., Takaoka, M., Okawa, T., Nobuhisa, T., Gunduz, M., Tanaka, N., The role of heparanase in gastrointestinal cancer. Oncol. Rep. 14 (2005), 3–8.
152. Naparstek, Y., Cohen, I.R., Fuks, Z., Vlodavsky, I., Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 310 (1984), 241–244.
153. Napolitano, G., Ballabio, A., TFEB at a glance. J. Cell Sci. 129 (2016), 2475–2481.
154. Nardella, C., Lahm, A., Pallaoro, M., Brunetti, M., Vannini, A., Steinkuhler, C., Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43 (2004), 1862–1873.
155. Nobuhisa, T., Naomoto, Y., Takaoka, M., Tabuchi, Y., Ookawa, K., Kitamoto, D., Gunduz, E., Gunduz, M., Nagatsuka, H., Haisa, M., Matsuoka, J., Nakajima, M., Tanaka, N., Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem. Biophys. Res. Commun. 331 (2005), 175–180.
156. Novick, D., Barak, S., Ilan, N., Vlodavsky, I., Heparanase interacts with resistin and augments its activity. PLoS One, 9, 2014, e85944.
157. Ogishima, T., Shiina, H., Breault, J.E., Tabatabai, L., Bassett, W.W., Enokida, H., Li, L.C., Kawakami, T., Urakami, S., Ribeiro-Filho, L.A., Terashima, M., Fujime, M., Igawa, M., Dahiya, R., Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 11 (2005), 1028–1036.
158. Ogren, S., Lindahl, U., Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J. Biol. Chem. 250 (1975), 2690–2697.
159. Okada, Y., Yamada, S., Toyoshima, M., Dong, J., Nakajima, M., Sugahara, K., Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J. Biol. Chem. 277 (2002), 42488–42495.
160. Ostapoff, K.T., Awasthi, N., Cenik, B.K., Hinz, S., Dredge, K., Schwarz, R.E., Brekken, R.A., PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol. Cancer Ther. 12 (2013), 1190–1201.
161. Osterholm, C., Folkersen, L., Lengquist, M., Ponten, F., Renne, T., Li, J., Hedin, U., Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 226 (2013), 67–73.
162. Ostrovsky, O., Shimoni, A., Baryakh, P., Morgulis, Y., Mayorov, M., Beider, K., Shteingauz, A., Ilan, N., Vlodavsky, I., Nagler, A., Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J. Leukoc. Biol. 95 (2014), 677–688.
163. Ostrowski, M., Carmo, N.B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C.F., Schauer, K., Hume, A.N., Freitas, R.P., Goud, B., Benaroch, P., Hacohen, N., Fukuda, M., Desnos, C., Seabra, M.C., Darchen, F., Amigorena, S., Moita, L.F., Thery, C., Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12:Suppl. 19–30 (2010), 11–13.
164. Pala, D., Rivara, S., Mor, M., Milazzo, F.M., Roscilli, G., Pavoni, E., Giannini, G., Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology 26 (2016), 640–654.
165. Palumbo, A., Larocca, A., Genuardi, M., Kotwica, K., Gay, F., Rossi, D., Benevolo, G., Magarotto, V., Cavallo, F., Bringhen, S., Rus, C., Masini, L., Iacobelli, M., Gaidano, G., Mitsiades, C., Anderson, K., Boccadoro, M., Richardson, P., Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 95 (2010), 1144–1149.
166. Parish, C.R., Hindmarsh, E.J., Bartlett, M.R., Staykova, M.A., Cowden, W.B., Willenborg, D.O., Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. Immunol. Cell Biol. 76 (1998), 104–113.
167. Parish, C.R., Freeman, C., Hulett, M.D., Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471 (2001), M99–M108.
168. Parish, C.R., The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6 (2006), 633–643.
169. Parish, C.R., Freeman, C., Ziolkowski, A.F., He, Y.Q., Sutcliffe, E.L., Zafar, A., Rao, S., Simeonovic, C.J., Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation. Matrix Biol. 32 (2013), 228–233.
170. Peinado, H., Lavotshkin, S., Lyden, D., The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21 (2011), 139–146.
171. Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., Nitadori-Hoshino, A., Hoffman, C., Badal, K., Garcia, B.A., Callahan, M.K., Yuan, J., Martins, V.R., Skog, J., Kaplan, R.N., Brady, M.S., Wolchok, J.D., Chapman, P.B., Kang, Y., Bromberg, J., Lyden, D., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18 (2012), 883–891.
172. Peterson, S.B., Liu, J., Unraveling the specificity of heparanase utilizing synthetic substrates. J. Biol. Chem. 285 (2010), 14504–14513.
173. Peterson, S., Liu, J., Deciphering mode of action of heparanase using structurally defined oligosaccharides. J. Biol. Chem. 287 (2012), 34836–34843.
174. Petrovich, E., Feigelson, S.W., Stoler-Barak, L., Hatzav, M., Solomon, A., Bar-Shai, A., Ilan, N., Li, J.P., Engelhardt, B., Vlodavsky, I., Alon, R., Lung ICAM-1 and ICAM-2 support spontaneous intravascular effector lymphocyte entrapment but are not required for neutrophil entrapment or emigration inside endotoxin-inflamed lungs. FASEB J. 30 (2016), 1767–1778.
175. Picardo, S.L., Maher, S.G., O'Sullivan, J.N., Reynolds, J.V., Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig. Surg. 29 (2012), 251–260.
176. Pikas, D.S., Li, J.-p., Vlodavsky, I., Lindahl, U., Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273 (1998), 18770–18777.
177. Pisano, C., Vlodavsky, I., Ilan, N., Zunino, F., The potential of heparanase as a therapeutic target in cancer. Biochem. Pharmacol. 89 (2014), 12–19.
178. Planer, D., Metzger, S., Zcharia, E., Wexler, I.D., Vlodavsky, I., Chajek-Shaul, T., Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice. PLoS One, 6, 2011, e18370.
179. Poon, I.K., Goodall, K.J., Phipps, S., Chow, J.D., Pagler, E.B., Andrews, D.M., Conlan, C.L., Ryan, G.F., White, J.A., Wong, M.K., Horan, C., Matthaei, K.I., Smyth, M.J., Hulett, M.D., Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. Eur. J. Immunol. 44 (2014), 1016–1030.
180. Proskuryakov, S.Y., Gabai, V.L., Mechanisms of tumor cell necrosis. Curr. Pharm. Des. 16 (2010), 56–68.
181. Purushothaman, A., Chen, L., Yang, Y., Sanderson, R.D., Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 283 (2008), 32628–32636.
182. Purushothaman, A., Uyama, T., Kobayashi, F., Yamada, S., Sugahara, K., Rapraeger, A.C., Sanderson, R.D., Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115 (2010), 2449–2457.
183. Purushothaman, A., Bandari, S.K., Liu, J., Mobley, J.A., Brown, E.E., Sanderson, R.D., Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome–cell interactions. J. Biol. Chem. 291 (2016), 1652–1663.
184. Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
185. Ramani, V.C., Yang, Y., Ren, Y., Nan, L., Sanderson, R.D., Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 286 (2011), 6490–6499.
186. Ramani, V.C., Pruett, P.S., Thompson, C.A., Delucas, L.D., Sanderson, R.D., Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J. Biol. Chem. 287 (2012), 9952–9961.
187. Ramani, V.C., Purushothaman, A., Stewart, M.D., Thompson, C.A., Vlodavsky, I., Au, J.L., Sanderson, R.D., The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 280 (2013), 2294–2306.
188. Ramani, V.C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G., Sanderson, R.D., Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 7 (2015), 1598–1607.
189. Ramani, V.C., Vlodavsky, I., Ng, M., Zhang, Y., Barbieri, P., Noseda, A., Sanderson, R.D., Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol., 2016 (PMID: 27016342).
190. Riaz, A., Ilan, N., Vlodavsky, I., Li, J.P., Johansson, S., Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J. Biol. Chem. 288 (2013), 12366–12375.
191. Ritchie, J.P., Ramani, V.C., Ren, Y., Naggi, A., Torri, G., Casu, B., Penco, S., Pisano, C., Carminati, P., Tortoreto, M., Zunino, F., Vlodavsky, I., Sanderson, R.D., Yang, Y., SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 17 (2011), 1382–1393.
192. Rivara, S., Milazzo, F.M., Giannini, G., Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med. Chem. 8 (2016), 647–680.
193. Rosenfeldt, M.T., Ryan, K.M., The multiple roles of autophagy in cancer. Carcinogenesis 32 (2011), 955–963.
194. Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P., David, G., Heparanase activates the syndecan–syntenin–ALIX exosome pathway. Cell Res. 25 (2015), 412–428.
195. Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P., David, G., Heparanase activates the syndecan–syntenin–ALIX exosome pathway. Cell Res. 25 (2015), 412–428.
196. Sanderson, R.D., Iozzo, R.V., Targeting heparanase for cancer therapy at the tumor–matrix interface. Matrix Biol. 31 (2012), 283–284.
197. Sanderson, R.D., Yang, Y., Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25 (2008), 149–159.
198. Sasaki, N., Higashi, N., Taka, T., Nakajima, M., Irimura, T., Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J. Immunol. 172 (2004), 3830–3835.
199. Schmidt, E.P., Yang, Y., Janssen, W.J., Gandjeva, A., Perez, M.J., Barthel, L., Zemans, R.L., Bowman, J.C., Koyanagi, D.E., Yunt, Z.X., Smith, L.P., Cheng, S.S., Overdier, K.H., Thompson, K.R., Geraci, M.W., Douglas, I.S., Pearse, D.B., Tuder, R.M., The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat. Med. 18 (2012), 1217–1223.
200. Schwarz, M., Munzel, P.A., Braeuning, A., Non-melanoma skin cancer in mouse and man. Arch. Toxicol. 87 (2013), 783–798.
201. Scott, D.W., Gascoyne, R.D., The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14 (2014), 517–534.
202. Secchi, M.F., Masola, V., Zaza, G., Lupo, A., Gambaro, G., Onisto, M., Recent data concerning heparanase: focus on fibrosis, inflammation and cancer. Biomol. Concepts 6 (2015), 415–421.
203. Settembre, C., Zoncu, R., Medina, D.L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M.C., Facchinetti, V., Sabatini, D.M., Ballabio, A., A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31 (2012), 1095–1108.
204. Shafat, I., Ben-Arush, M.W., Issakov, J., Meller, I., Naroditsky, I., Tortoreto, M., Cassinelli, G., Lanzi, C., Pisano, C., Ilan, N., Vlodavsky, I., Zunino, F., Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J. Cell. Mol. Med. 15 (2011), 1857–1864.
205. Shain, K.H., Dalton, W.S., Tao, J., The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 34 (2015), 4673–4682.
206. Shteingauz, A., Ilan, N., Vlodavsky, I., Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and alpha-actinin. J. Cell. Mol. Life Sci. (CMLS) 71 (2014), 4457–4470.
207. Shteingauz, A., Boyango, I., Naroditsky, I., Hammond, E., Gruber, M., Doweck, I., Ilan, N., Vlodavsky, I., Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res. 75 (2015), 3946–3957.
208. Shteper, P.J., Zcharia, E., Ashhab, Y., Peretz, T., Vlodavsky, I., Ben-Yehuda, D., Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22 (2003), 7737–7749.
209. Simizu, S., Ishida, K., Osada, H., Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 95 (2004), 553–558.
210. Simons, M., Raposo, G., Exosomes—vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21 (2009), 575–581.
211. Sonoda, R., Naomoto, Y., Shirakawa, Y., Fujiwara, Y., Yamatsuji, T., Noma, K., Tanabe, S., Takaoka, M., Gunduz, M., Tsujigiwa, H., Nagatsuka, H., Ohara, N., Yoshino, T., Takubo, K., Vieth, M., Tanaka, N., Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 57 (2010), 90–100.
212. Stoler-Barak, L., Petrovich, E., Aychek, T., Gurevich, I., Tal, O., Hatzav, M., Ilan, N., Feigelson, S.W., Shakhar, G., Vlodavsky, I., Alon, R., Heparanase of murine effector lymphocytes and neutrophils is not required for their diapedesis into sites of inflammation. FASEB J. 29 (2015), 2010–2021.
213. Tayel, A., Abd El Galil, K.H., Ebrahim, M.A., Ibrahim, A.S., El-Gayar, A.M., Al-Gayyar, M.M., Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur. J. Pharmacol. 728 (2014), 151–160.
214. Thompson, C.A., Purushothaman, A., Ramani, V.C., Vlodavsky, I., Sanderson, R.D., Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J. Biol. Chem. 288 (2013), 10093–10099.
215. Timpl, R., Brown, J.C., Supramolecular assembly of basement membranes. Bioessays 18 (1996), 123–132.
216. Tkach, M., Théry, C., Communication by extracellular vesicles: where we are and where we need to go. Cell 164 (2016), 1226–1232.
217. Tkachenko, E., Rhodes, J.M., Simons, M., Syndecans: new kids on the signaling block. Circ. Res. 96 (2005), 488–500.
218. van den Hoven, M.J., Rops, A.L., Bakker, M.A., Aten, J., Rutjes, N., Roestenberg, P., Goldschmeding, R., Zcharia, E., Vlodavsky, I., van der Vlag, J., Berden, J.H., Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 70 (2006), 2100–2108.
219. van den Hoven, M.J., Rops, A.L., Vlodavsky, I., Levidiotis, V., Berden, J.H., van der Vlag, J., Heparanase in glomerular diseases. Kidney Int. 72 (2007), 543–548.
220. Vincent Rajkumar, S., Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 89 (2014), 999–1009.
221. Vlodavsky, I., Friedmann, Y., Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Investig. 108 (2001), 341–347.
222. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P., Fuks, Z., Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?. Trends Biochem. Sci. 16 (1991), 268–271.
223. Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., Lider, O., Naparstek, Y., Cohen, I.R., Fuks, Z., Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12 (1992), 112–127.
224. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., Pecker, I., Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5 (1999), 793–802.
225. Vlodavsky, I., Beckhove, P., Lerner, I., Pisano, C., Meirovitz, A., Ilan, N., Elkin, M., Significance of heparanase in cancer and inflammation. Cancer Microenviron. 5 (2012), 115–132.
226. Vlodavsky, I., Blich, M., Li, J.P., Sanderson, R.D., Ilan, N., Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol. 32 (2013), 241–251.
227. Vreys, V., David, G., Mammalian heparanase: what is the message?. J. Cell. Mol. Med. 11 (2007), 427–452.
228. Vreys, V., Delande, N., Zhang, Z., Coomans, C., Roebroek, A., Durr, J., David, G., Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J. Biol. Chem. 280 (2005), 33141–33148.
229. Wang, Z., Xu, H., Jiang, L., Zhou, X., Lu, C., Zhang, X., Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod. Pathol. 18 (2005), 205–211.
230. Wang, G.Z., Tang, X.D., Lu, M.H., Gao, J.H., Liang, G.P., Li, N., Li, C.Z., Wu, Y.Y., Chen, L., Cao, Y.L., Fang, D.C., Yang, S.M., Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prev. Res. (Phila.) 4 (2011), 1285–1295.
231. Wang, F., Wan, A., Rodrigues, B., The function of heparanase in diabetes and its complications. Can. J. Diab. 37 (2013), 332–338.
232. Waterman, M., Ben-Izhak, O., Eliakim, R., Groisman, G., Vlodavsky, I., Ilan, N., Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod. Pathol. 20 (2007), 8–14.
233. Weinbaum, S., Tarbell, J.M., Damiano, E.R., The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 9 (2007), 121–167.
234. Weissmann, M., Arvatz, G., Horowitz, N., Feld, S., Naroditsky, I., Zhang, Y., Ng, M., Hammond, E., Nevo, E., Vlodavsky, I., Ilan, N., Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 704–709.
235. White, E., Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12 (2012), 401–410.
236. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase. Biochem. Biophys. Res. Commun. 443 (2014), 185–188.
237. Winterhoff, B., Freyer, L., Hammond, E., Giri, S., Mondal, S., Roy, D., Teoman, A., Mullany, S.A., Hoffmann, R., von Bismarck, A., Chien, J., Block, M.S., Millward, M., Bampton, D., Dredge, K., Shridhar, V., PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur. J. Cancer 51 (2015), 879–892.
238. Wojtuszkiewicz, A., Schuurhuis, G.J., Kessler, F.L., Piersma, S.R., Knol, J.C., Pham, T.V., Jansen, G., Musters, R.J., van Meerloo, J., Assaraf, Y.G., Kaspers, G.J., Zweegman, S., Cloos, J., Jimenez, C.R., Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol. Cell. Proteom. 15 (2016), 1281–1298.
239. Worthen, G.S., Schwab, B. 3rd, Elson, E.L., Downey, G.P., Mechanics of stimulated neutrophils: cell stiffening induces retention in capillaries. Science 245 (1989), 183–186.
240. Wu, W., Pan, C., Meng, K., Zhao, L., Du, L., Liu, Q., Lin, R., Hypoxia activates heparanase expression in an NF-kappaB dependent manner. Oncol. Rep. 23 (2010), 255–261.
241. Wu, W.K., Coffelt, S.B., Cho, C.H., Wang, X.J., Lee, C.W., Chan, F.K., Yu, J., Sung, J.J., The autophagic paradox in cancer therapy. Oncogene 31 (2012), 939–953.
242. Wu, L., Viola, C.M., Brzozowski, A.M., Davies, G.J., Structural characterization of human heparanase reveals insights into substrate recognition. Nat. Struct. Mol. Biol. 22 (2015), 1016–1022.
243. Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
244. Xiong, Z., Lu, M.H., Fan, Y.H., Cao, Y.L., Hu, C.J., Wu, Y.Y., Wang, S.M., Luo, G., Fang, D.C., Li, C., Yang, S.M., Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int. J. Oncol. 40 (2012), 1601–1609.
245. Yang, Y., Ren, Y., Ramani, V.C., Nan, L., Suva, L.J., Sanderson, R.D., Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res. 70 (2010), 8329–8338.
246. Young, E., The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 122 (2008), 743–752.
247. Yu, L., Wang, L., Chen, S., Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 14 (2010), 2592–2603.
248. Yu, L., Wang, L., Chen, S., Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim. Biophys. Acta 1835 (2013), 144–154.
249. Zcharia, E., Philp, D., Edovitsky, E., Aingorn, H., Metzger, S., Kleinman, H.K., Vlodavsky, I., Elkin, M., Heparanase regulates murine hair growth. Am. J. Pathol. 166 (2005), 999–1008.
250. Zcharia, E., Zilka, R., Yaar, A., Yacoby-Zeevi, O., Zetser, A., Metzger, S., Sarid, R., Naggi, A., Casu, B., Ilan, N., Vlodavsky, I., Abramovitch, R., Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 19 (2005), 211–221.
251. Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Processing and activation of latent heparanase occurs in lysosomes. J. Cell Sci. 117 (2004), 2249–2258.
252. Zetser, A., Bashenko, Y., Edovitsky, E., Levy-Adam, F., Vlodavsky, I., Ilan, N., Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 66 (2006), 1455–1463.
253. Zhang, H.G., Grizzle, W.E., Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 17 (2011), 959–964.
254. Zhang, Y., Ryan, D.S., Bower, K.S., Ilan, N., Vlodavsky, I., Laurie, G.W., Focus on molecules: heparanase. Exp. Eye Res. 91 (2010), 476–477.
255. Zhang, Y.F., Tang, X.D., Gao, J.H., Fang, D.C., Yang, S.M., Heparanase: a universal immunotherapeutic target in human cancers. Drug Discov. Today 16 (2011), 412–417.
256. Zhang, J., Yang, J., Han, X., Zhao, Z., Du, L., Yu, T., Wang, H., Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: potential for therapy. Oncol. Lett. 4 (2012), 178–182.
257. Zhang, X., Wang, B., O'Callaghan, P., Hjertstrom, E., Jia, J., Gong, F., Zcharia, E., Nilsson, L.N., Lannfelt, L., Vlodavsky, I., Lindahl, U., Li, J.P., Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain. Acta Neuropathol. 124 (2012), 465–478.
258. Zhang, X., Wang, B., Li, J.P., Implications of heparan sulfate and heparanase in neuroinflammation. Matrix Biol. 35 (2014), 174–181.
259. Zhang, L., Ngo, J.A., Wetzel, M.D., Marchetti, D., Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 17 (2015), 101–113.
260. Zheng, Y., Yang, J., Qian, J., Qiu, P., Hanabuchi, S., Lu, Y., Wang, Z., Liu, Z., Li, H., He, J., Lin, P., Weber, D., Davis, R.E., Kwak, L., Cai, Z., Yi, Q., PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27 (2013), 702–710.
261. Zhitomirsky, B., Assaraf, Y.G., Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 20:6 (2015), 1143–1156.
262. Zhitomirsky, B., Assaraf, Y.G., Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updat. 24 (2016), 23–33.
263. Zhou, H., Roy, S., Cochran, E., Zouaoui, R., Chu, C.L., Duffner, J., Zhao, G., Smith, S., Galcheva-Gargova, Z., Karlgren, J., Dussault, N., Kwan, R.Y., Moy, E., Barnes, M., Long, A., Honan, C., Qi, Y.W., Shriver, Z., Ganguly, T., Schultes, B., Venkataraman, G., Kishimoto, T.K., M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One, 6, 2011, e21106.
264. Zhou, W., Yang, Y., Xia, J., Wang, H., Salama, M.E., Xiong, W., Xu, H., Shetty, S., Chen, T., Zeng, Z., Shi, L., Zangari, M., Miles, R., Bearss, D., Tricot, G., Zhan, F., NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 23 (2013), 48–62.
265. Ziolkowski, A.F., Popp, S.K., Freeman, C., Parish, C.R., Simeonovic, C.J., Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J. Clin. Investig. 122 (2012), 132–141.